Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Melanoma 27Neoplasm Metastasis 16Skin Neoplasms 12Breast Neoplasms 9Multiple Myeloma 8Kidney Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Pancreatic Neoplasms 7Ovarian Neoplasms 7Lymphoma 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Hematologic Neoplasms 7Neoplasms 6Myelodysplastic Syndromes 6Leukemia, Myeloid, Acute 6Uterine Cervical Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, B-Cell 5Carcinoma, Non-Small-Cell Lung 5Urogenital Neoplasms 4Stomach Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Gastrointestinal Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Vaginal Neoplasms 2Rectal Neoplasms 2

Interventions

Doxorubicin 4Cyclophosphamide 4fludarabine phosphate 3Vorinostat 3Vincristine 3Etoposide 3Rituximab 2Prednisone 2Pharmacogenomic Testing 2MK 2206 2Cyclosporine 2Busulfan 2Bortezomib 2Bevacizumab 2Antilymphocyte Serum 2veliparib 1vandetanib 1temsirolimus 1tanespimycin 1siplizumab 1romidepsin 1obatoclax 1liposomal doxorubicin 1gossypol acetic acid 1ganitumab 1fludarabine 1duvelisib 1cediranib 1cc-486 1belinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Extranodal NK-T-Cell × fludarabine × Clear all
NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡